These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17307094)

  • 21. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 22. [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
    Golay A
    Rev Med Suisse; 2008 Aug; 4(168):1828. PubMed ID: 18814768
    [No Abstract]   [Full Text] [Related]  

  • 23. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of rimonabant on weight reduction and cardiovascular risk.
    van Oosten B; Killestein J; Polman Ch
    Lancet; 2005 Jul 30-Aug 5; 366(9483):368-9; author reply 369-70. PubMed ID: 16054933
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibitors of cannabinoid receptors and glucose metabolism.
    Scheen AJ; Paquot N
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacology of cannabinoid receptors].
    Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
    Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2007 Feb; 62(2):81-5. PubMed ID: 17461296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
    Gadde KM; Allison DB
    Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
    [No Abstract]   [Full Text] [Related]  

  • 31. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
    Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
    [No Abstract]   [Full Text] [Related]  

  • 32. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of rimonabant on weight reduction and cardiovascular risk.
    Hirschel B
    Lancet; 2005 Jul 30-Aug 5; 366(9483):369; author reply 369-70. PubMed ID: 16054934
    [No Abstract]   [Full Text] [Related]  

  • 34. Rimonabant: obituary for a wonder drug.
    Boekholdt SM; Peters RJ
    Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
    [No Abstract]   [Full Text] [Related]  

  • 35. Another pill for weight reduction.
    Conti CR
    Clin Cardiol; 2005 Feb; 28(2):59-60. PubMed ID: 15757073
    [No Abstract]   [Full Text] [Related]  

  • 36. The element of surprise.
    Piomelli D
    Nat Med; 2008 Jul; 14(7):720-1. PubMed ID: 18607371
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant.
    Heppenstall C; Bunce S; Smith JC
    Nutr J; 2012 Jul; 11():50. PubMed ID: 22824101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does rimonabant independently affect free fatty acid and glucose metabolism?
    Triay J; Mundi M; Klein S; Toledo FG; Smith SR; Abu-Lebdeh H; Jensen M
    J Clin Endocrinol Metab; 2012 Mar; 97(3):819-27. PubMed ID: 22170727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.
    Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422
    [No Abstract]   [Full Text] [Related]  

  • 40. [Rimonabant (Acomplia)].
    Duh D; Vanddevijver A
    J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.